# Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis

> **NCT04539639** · PHASE2 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 166 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Jaktinib
- **DRUG:** Jaktinib
- **DRUG:** Jaktinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04539639
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-02
- **Primary completion:** 2022-05-19
- **Final completion:** 2022-05-19
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04539639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04539639, "Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04539639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*